The memo that went out to OpenAI employees on the evening of July 9 opened with a personal disclosure. Fidji Simo, the executive who runs the company’s consumer applications, wrote that she had been on medical leave for about three months, that a chronic illness had worsened, and that she had decided she could no longer hold a full-time role. She would step back to become a part-time adviser.
OpenAI confirmed the change on July 10. Simo, who joined the company in late 2024 after serving as chief executive of the grocery-delivery company Instacart, said the decision followed a difficult recovery period and that she intends to put her health first. She will keep a formal connection to OpenAI, advising on product direction, while also devoting herself to the biotechnology work she has pursued alongside her career in consumer technology.
Her note did not hide the strain. Simo said the illness flared during a period when her job carried an unusual weight: she oversaw the consumer products that made OpenAI the fastest-growing software company in the industry, and she did so through two years of breakneck product releases, regulatory scrutiny and internal turbulence.
Before OpenAI, Simo built a reputation as one of the most aggressive product executives in Silicon Valley. At Meta, she ran the Facebook app, where she pushed the social network toward short-form video and remade the News Feed into a recommendation engine. At Instacart, she took a pandemic-era delivery business through a public listing. She left Instacart in 2024 to join OpenAI at a moment when the company was reorganizing around its consumer franchise, and she quickly became the public face of ChatGPT’s product strategy.
Her departure from the day-to-day comes at a consequential moment for OpenAI. The same week she announced her transition, the company released GPT-5.6 in three tiers and launched ChatGPT Work, an agent product designed to execute complex workflows without step-by-step human instruction. Simo’s announcement and the product launch landed within 48 hours of each other, and people close to the company said the timing was coincidental but awkward, forcing executives to answer questions about continuity on the biggest product week of the quarter.
Simo said her commitment to OpenAI’s mission is unchanged. She will continue to work with the company on artificial intelligence in health care, an area where OpenAI has been building partnerships with hospitals, drug developers and clinical research organizations. She also sits on the board of a biotech venture focused on applying AI to drug discovery, and she said she expects to spend more of her time there.
Her background makes the timing of her exit notable. Simo was hired to bring consumer discipline to a research-driven company, and she arrived with a reputation for shipping products quickly and cutting the ones that did not work. Colleagues said she was a driving force behind the push to make ChatGPT a daily habit rather than a curiosity, and her product instincts shaped the app’s expansion into voice, image and agentic features. That she leaves the operating role as those features mature, rather than at the start of the buildout, gives her departure a sense of completion that is rare in the industry.
Her move fits a pattern taking shape across the frontier AI labs. Senior executives at OpenAI, Anthropic and Google DeepMind have cycled in and out of operating roles as the companies grow past the startup phase, and several have opted for advisory positions rather than clean exits, keeping equity and influence while shedding day-to-day management. Headhunters said the part-time adviser title is becoming the standard off-ramp for exhausted executives at the top of the industry.
Industry analysts said the health-care focus is strategic as well as personal. AI-driven drug discovery has moved from academic experiments to commercial pipelines, with a handful of startups reporting clinical-stage candidates designed in part by large language models. OpenAI has signaled that health is one of its priority verticals, and Simo’s continued involvement, even part-time, keeps a senior voice on that work.
The company said it does not expect the transition to change its consumer-product plans. The applications organization will report through existing leadership while OpenAI considers how to fill the role, and people familiar with the matter said no immediate restructuring is planned. Simo’s own framing was simpler. In her note, she said she will keep supporting the mission, keep pushing AI into medicine, and, for the first time in years, keep her calendar open.
For a company whose public narrative is built around relentless acceleration, the departure of a senior executive for health reasons also exposes the human cost of that pace. Simo asked for privacy for herself and her family. Her colleagues, she wrote, should expect to see less of her, and more of the work.
